Icagen, Inc. - Common Stock

Icagen , a biopharmaceutical company , has initiated a Phase II proof - of - concept clinical trial to evaluate the safety and efficacy of senicapoc , the company's orally available small molecule ...

On The Wires Icagen ( ICGN ) announces the start of a Phase II proof - of - concept clinical trial to evaluate the safety and efficacy of senicapoc , the Company's novel orally available small ...

RESEARCH TRIANGLE PARK , NC , Oct . 9 , 2008 ( GLOBE NEWSWIRE ) - - Icagen , Inc . ( Nasdaq : ICGN ) announced today the start of a Phase II proof - of - concept clinical trial to evaluate the ...

, , ) reported today , at the 15th International Inflammation Research Association Conference in Chantilly , Virginia , results from a preclinical study demonstrating effects of senicapoc in ...

LONG BEACH ( Mffais . com ) - Vanguard Group Inc sold - 128,929 ( - 99.84 % ) of their shares in Icagen Inc ( ICGN ) , bringing their current holdings to 205 shares as shown by filings made public ...